Corrigendum to “European-evidence-based consensus on the management of ulcerative colitis: Current management” [J Crohns & Colitis 2 (2008) 24–62]

Refers to article:

European evidence-based Consensus on the management of ulcerative colitis: Special situations , 29 January 2008
Livia Biancone, Pierre Michetti, Simon Travis, Johanna C. Escher, Gabriele Moser, Alastair Forbes, Jörg C Hoffmann, Axel Dignass, Paolo Gionchetti, Günter Jantschek, Ralf Kiesslich, Sanja Kolacek, Rod Mitchell, Julian Panes, Johan Soderholm, Boris Vucelic, Eduard Stange, for the European Crohn's and Colitis Organisation (ECCO)
Journal of Crohn's and Colitis
March 2008 (Vol. 2, Issue 1, Pages 63-92)
Full Text | Full-Text PDF (544 KB)

Article Outline

• Copyright

The Publisher and Authors regret and apologise that Table 6.5 on page 45 was incorrectly printed. The corrected table is:

Table 6.5.

Randomized trials of probiotics for maintaining remission in UC


Author [ref]	Year	Number of patients	Study drugs	Dosage	Duration (months)	Failure to maintain clinical or endoscopic remission
Kruis274	1997	120	E. coli Nissle	200 mg/day	3	16%
Kruis274	1997	120	Mesalazine	1.5 g/day		11%
Rembacken275	1999	116	E. coli Nissle	200 mg/day	12	67%
Rembacken275	1999	116	Mesalazine	1.2 g/day		73%
Kruis276	2004	327	E. coli Nissle	200 mg/day	12	45%
Kruis276	2004	327	Mesalazine	1.5 g/day		37%
Ishikawa277	2000	21	Probiotic mixturea number	100 mL	12	27%
Ishikawa277	2000	21	Treatmentb			90%
Zocco278	2006	187	Lactobacillus GG	18×109	12	15%
			Mesalazine	2.4 g/day		20%
			Combination			16%

Bifidobacterium bifidum+Bifidobacterium breve+Lactobacillus acidophilus.

Open label study.

Corresponding authors. Travis is to be contacted at Tel.: +44 1865 228753; fax: +44 1865 228763. Stange, Tel: +49 0711 81013404; fax: +49 0711 81013793.

1 These authors acted as convenors of the Consensus and contributed equally to the work.

PII: S1873-9946(08)00029-9

doi:10.1016/j.crohns.2008.03.001

14 of 16